Type 1 Diabetes Clinical Research

Study Coordinator: Megan Kirchner, CCRP
Open for enrollment: Yes

A research study for people with two or more autoantibodies (identified through the TrialNet Pathway to Prevention) and normal glucose tolerance based on results from oral glucose tolerance testing (OGTT). We are testing whether Hydroxychloroquine will protect beta cells from the immune system attack that leads to Type 1 diabetes.

Study coordinator: Sophia Markoff
Open for enrollment: Yes

The purpose of this observational study is to detect Type 1 diabetes at its earliest stages. Family members of people with Type 1 diabetes are screened for autoantibodies associated with Type 1 diabetes development.

Study Coordinator: Sophia Markoff
Open for enrollment: Yes

T1D is characterized by the autoimmune destruction of insulin-producing pancreatic β-cells. The purpose of this study is to examine the broad range of pancreas sizes in those with T1D risk to evaluate if a change from baseline over a defined time-period may provide the best sensitivity in estimating diabetes risk.

Study Coordinator:  Corinne Parks-Schenck, BSN, RN

Open for enrollment: Yes

The purpose of this study is to develop and validate biomarkers that predict T1D disease risk and document disease progression based on blood and urine indicators of beta cell stress and death in persons with emerging and established T1D.

Study Coordinator: Katelyn Hagen
Open for enrollment: Yes The purpose of this study is to determine the effects of prebiotics on the gut microbiome and beta cell function in children recently diagnosed with type 1 diabetes.

Children eligible for this study must:

• Be between 12-<17 years old •
• Have been diagnosed with T1D within the past 4-24 months

Study Coordinator: Corinne Parks-Schenck, BSN, RN
Open for enrollment: Yes

This research is studying an investigational drug called Ladarixin to see if it is effective in preserving β-cell function and delaying the progression of T1D in adolescent and adult patients ages 14-45.
Eligibility requirements:

• New onset Type 1 Diabetes (must receive 1st dose within 180 days of start of insulin therapy)
• Positive for at least one diabetes antibody
• Currently using insulin via injections or pump therapy
• Fasting C-Peptide < 0.205 nmol/L

 

Study Coordinator: Dana Chatila
Open for enrollment: Yes

The purpose of this study is to find out whether an inhaled, ultra rapid-acting insulin works as rapid-acting injections.

Children eligible for this study must:

• Have type 1 or type 2 diabetes
• Be at least 4 years old and less than 18 years at the start of the study
• Use daily insulin injections
• HbA1c levels between 7% and 11%

Study Coordinator: Ellie Ryan
Open for enrollment: Yes

A research study studying the effect Type 1 Diabetes has on bone health and the gut microbiome. To be eligible, you must be age 12-20, have a HBA1c greater than 6.5% and have been diagnosed with T1D for at least 2 years.

Study Coordinator: Dana Chatila
Open for enrollment: Yes

This research study is evaluating an investigational drug called nasal glucagon to see if it can safely increase blood sugar levels in children with Type 1 Diabetes (T1D) aged 1 to less than 4 years.

Eligibility requirements are:

• At least 1 year old and will not turn 4 before the end of the study
• Were diagnosed with Type 1 Diabetes at least 6 months ago
• Have been receiving insulin therapy via a pump or daily injections, and have been stable on therapy for at least 3 months before the start of the study
• Are in otherwise good general health with no structural abnormalities in the nose or nasal cavity
• Are able to give blood for the laboratory testing Have NOT had severe hypoglycemia (very low blood sugar) that required immediate administration of carbohydrate or glucagon in the 3 months before the start of the study
• Do NOT have any presence or history of hypersensitivity to glucagon or related products or severe hypersensitivity to any other medication

Study coordinator: Sarah Holloway
Open for enrollment: Yes

With consent from participants the Type 1 Diabetes Research Team collects and securely stores information to determine eligibility for future research studies. If a person in the database appears to meet criteria for inclusion in a future study, they can be contacted by the research team to see if they would like additional information about participating.

Study Coordinator: Katelyn Hagen

Open for Enrollment: Yes The purpose of this observational study is to profile the gut microbiome in youth with type 1 diabetes according to weight categories and then determine if differences in the gut microbiome profile are associated with differences in measures of β-cell stress and death. Eligibility requirements: Youth 11-18 years of age with T1D at time of enrollment

Study Coordinator: Dana Chatila
Open for enrollment: Yes

This research study is evaluating an investigational drug called nasal glucagon to see if it can safely increase blood sugar levels in children with Type 1 Diabetes (T1D) aged 1 to less than 4 years.

Eligibility requirements are:

• At least 1 year old and will not turn 4 before the end of the study
• Were diagnosed with Type 1 Diabetes at least 6 months ago
• Have been receiving insulin therapy via a pump or daily injections, and have been stable on therapy for at least 3 months before the start of the study
• Are in otherwise good general health with no structural abnormalities in the nose or nasal cavity
• Are able to give blood for the laboratory testing Have NOT had severe hypoglycemia (very low blood sugar) that required immediate administration of carbohydrate or glucagon in the 3 months before the start of the study
• Do NOT have any presence or history of hypersensitivity to glucagon or related products or severe hypersensitivity to any other medication

Study Coordinator: Corinne Parks-Schenck, BSN, RN
Open for enrollment: Yes

The purpose of this Phase 1 study is to test the safety of a new treatment intended to slow down or stop diabetes in people at high risk before clinical diagnosis. The treatment is a plasmid vector designed to transfer DNA into cells where it can communicate with the immune system. Earlier lab studies show this treatment might retrain the immune system to stop its attack on the insulin-producing beta cells.

Eligibility requirements: Ages 18-45 and a T1D diagnosis in the past 48 months

Study Coordinator: Dana Chatila
Open for enrollment: Yes

The purpose of this study is to find out whether an inhaled, ultra rapid-acting insulin works as rapid-acting injections.

Children eligible for this study must:

• Have type 1 or type 2 diabetes
• Be at least 4 years old and less than 18 years at the start of the study
• Use daily insulin injections
• HbA1c levels between 7% and 11%